#1/11 BenevolentAl: Complex biology, unlocked J.P Morgan Healthcare Conference Joanna Shields, CEO, BenevolentAl 9 January 2023 ΑΙ Benevolent#2Disclaimer Forward-Looking Statements This document may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "should" and similar expressions. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; economic outlook and industry trends; developments in BenevolentAl's markets; the impact of regulatory initiatives; and/or the strength of BenevolentAl's competitors. These forward-looking statements reflect, at the time made, BenevolentAl's beliefs, intentions and current targets/aims. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this release are based upon various assumptions based on, without limitation, management's examination of historical operating trends, data contained in BenevolentAl's records, and third-party data. Although BenevolentAl believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond BenevolentAl's control. Forward-looking statements are not guarantees of future performance and such risks, uncertainties, contingencies and other important factors could cause the actual outcomes and the results of operations, financial condition and liquidity of BenevolentAl or the industry to differ materially from those results expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date of this release. No representation or warranty is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved. Benevolent 2#3A clinical-stage Al-enabled drug discovery company SCIENTIFIC VALIDATION 15 3 1 10+ named Platform-generated drug programmes assets in pre-IND asset in Phase II exploratory stage programmes COMMERCIAL VALIDATION 5 novel targets selected for AstraZeneca's portfolio REGULATORY VALIDATION FDA approval of COVID-19 treatment identified by BenevolentAl Benevolent 3#4GC We are drowning in a sea of data and starving for knowledge Sydney Brenner The Nobel Prize winner in Physiology of Medicine 2002#5DATA FOUNDATIONS Generating a 360° view of disease biology Experiments Assay Data (Binding, Omics Comparison, CRISPR Screens) Clinical Trial OMICS Genes Proteins Isoforms Transcripts & Variants Biological Systems Cellular Component Molecular Function Biological Process Mechanism Pathways Literature Scientific Literature Patent Literature Regulatory Documents Aetiology Diseases Symptoms Molecules Organic Compounds Preclinical Candidates Approved Drugs Antibodies Other Biologics Pharmacology Pharmacokinetics Multimodal approach combines over 85 data sources to provide a holistic view of disease biology Maximise our probability of clinical success by integrating disease traits, genetics and genomics data to generate endotype-specific target predictions Breaks down silos across therapeutic areas to connect shared mechanisms across disease Provides a proprietary integrated view of biomedical data that supports discovery and decision-making Benevolent 5#6The Benevolent Platform™ 99900000 ☐☐☐☐☐☐☐☐ 85+ DATA SOURCES L 00000 Comprehensive data foundations DATA FOUNDATIONS ●OO 000 STRUCTURED DATA PORN <>. BOUGHT LITERATURE KATIKA.. B PATIENT DATA 33+ ENTITY. TYPES DISEASE EXPLORATION Can we treat ALS by reversing Autophagy impairment in microglia by reducing oxidative stress? [000 Target Endpoint What we will measure Cell type Mechanism Sign Biology first TARGET IDENTIFICATION TARGET PREDICTIONS Vo A LARGE LANGUAGE MODEL GRAPH MODELS GENETIC & GENOMIC MODELS DATA QUERIES TRANSCRIPTOMICS ✓Hypothesis driven MODELS TARGET ASSESSMENT Ⓒ O Small Molecule (X) NOVELTY ?PATENT LANDSCAPE (X) Alternative Modalities ✓✓ TRACTABILITY (?) SELECTIVITY TARGET VALIDATION Portfolio Entry Benevolent 6#7DEMO Disease Exploration Mechanisms There are 869 Mechanisms related to amyotrophic lateral sclerosis Recommended entities are listed in ascending order of Rank by default. Cluster mechanisms Mechanism name RNA localization to nucleus Filter by: + Related tissues: All Diseases related to amyotrophic lateral sclerosis Rating O ↓ 100% V Data relevance score → Entity Explorer • 0.99 ALS Demo Disease program: ALS demo Data release: 1-42 (latest) Number of entities: 3 Number of unique benchmark genes: 853 530 155 234 amyotrophic lateral sclerosis Disease + Add new entity astrocyte activation Mechanism (GeneOntology) 198 Explore Visualise cellular response to oxidative stress Mechanism (GeneOntology) Related cell: All v Number of benchmark genes Save amyotrophic lateral sclerosis N Disease 245 Saved Shortlists Venn diagram Upset diagram Display geneset genes i Mechanisms Mechanism ontology: All Number of geneset genes amyotrophic lateral sclerosis 530 genes Diseases 51 There are 869 Mechanisms related to amyotrophic lateral sclerosis astrocyte activation 155 genes Benchmark gene overlap related to amyotrophic lateral sclerosis Genetic Evidence: All cellular response to oxidative stress. 234 genes Genetic evidence No Related cell: All Entity definition Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized degeneration of motor neurons in the primary motor cortex, corticospinal tracts, br Benchmark Genes Geneset Genes There are 530 benchmark genes in your selection: SLC18A3, LGALS4, MFN2, LHX3, SYNCRIP, LANCL1, KPNB1, SNCG, CLP1, MADD, S ZNF512B. SNCA, TSPO, SODI. SARMI Show all 530 benchmark genes + Add as new custom list (530) Number of benchmark genes Ⓒ 198 Mechanism ontology. All Number of geneset genes → 245 V Genetic Evidence: All V Benchmark gene overlap 51 Genetic evidence O No Benevolent 7#8DEMO Disease Exploration Network View PPI Edge Details emo 8 NFE2L2 up regulates SOD1 Edge source: SigNOR via transcriptional regulation Explore ▸ mark genes: 956 lateral Visualise + NFE2L2 - SOD1 There are 1 edges describing 1 kinds of interaction between NFE2L2 and SOD1 AKT1 Saved Shortlists X Nt HSPB1 PUOVNE + HSF1 O HSPA/ ATF4 20 SIGMARI DDIT3 PEA15 PPI Edge Details CAMK2A coz NFE2L2 SOD1 There are 1 edges describing 1 kinds of interaction between NFE2L2 and SOD1 NFE2L2 up regulates SOD1 Edge source: SigNOR via transcriptional regulation SQST 11 O GFAP GABARA /DFY3 NAP1 O U MAPILMAPILC3C FYCO TP53INPY BACHMARK REK CON X Nt How much do shortlisted er overlap? amvotronic interal semen 530 TLR4 Display geneset genes Colour communities Mechanisms activation Enrich network. Dis Enrich the network for Mecha button below Number of edges displayed Benevolent 8#9DISEASE EXPLORATION Understanding to build robust 000 40 000 disease biology hypotheses Target Endpoint: What we will measure Can we treat ALS by Sign reversing Autophagy impairment in microglia by reducing oxidative stress? Mechanism Cell type [T] Your biological question ... Provides an unprecedented view of the disease landscape Accelerates discovery of novel biology Surfaces potential targets and mechanisms that may not have otherwise been found Benevolent 9#10TARGET PREDICTIONS Multiple machine learning models expand the target universe LARGE LANGUAGE MODEL GRAPH MODELS GENETIC & GENOMIC MODELS DATA QUERIES TRANSCRIPTOMICS MODELS Expands pool of possible targets by approaching target identification from different angles: some models can rank the entire human genome, others provide promising targets that answer biological questions Reveals novel drug targets that have never been considered for a disease before Modality agnostic: the Benevolent PlatformTM can be applied to antibodies and other biologic agents, in addition to small molecules Benevolent 10#11TARGET TRIAGE Suite of Al tools enable data-driven decisions 70000 x (? O O O MAPKAPK2 Sek MAPK7 DYRKIA LDHA k) Bam Bak Chemical Space Plot for Druggability Devidence and for ACKRS (C O Aerod Solectivity 12% NOVELTY PATENT LANDSCAPE TRACTABILITY SELECTIVITY Empowers scientists to make data-driven decisions on which targets to take into experimental validation Scientists can assess key aspects for progressability including optimal modality, patent and competitive landscape and the druggability and selectivity potential Select targets that are most likely to succeed Benevolent 11#12DEMO Target Triage Triage criteria Biological Rationale 1 Ligandability 1 Safety 1 Tissue Expression Therapeutic Evidence ✰ Programs ALS demo Oxidative stress in ALS / ALS demo Filter Triage status Triaged (0) Assessment decision Match (5) Uncertain (5) Context Mechanism On other lists Present 1 Ligandability Not traged (12) Triage criteria Biological Rationale Safety Not match (2) Abs it Clear all Tissue Expression Therapeutic Evidence Tractability-class 4 (out of 4) Match GRM5 glutamate metabotropic receptor 5 Your comment (can be edited when changing target decision) Biological Rationale-class 3 (out of 4) Tractability-class 3 (out of 4) SLC7A11 solute carrier family 7 member 11 Biological Rationale-class 3 (out of 4) Uncertain Your comment (can be edited when changing target decision) Tractability-class 2 (out of 4) Uncertain Match NFE2L2 Biological Rationale-class 4 (out of 4) Tractability-class 4 (out of 4) Ligandability-cless 4 (out of 4) TRPV1 5 Target Rank? NFE2 like bZIP transcription factor 2 6 Ligandability-class 1 (out of 41 Biological Rationale-class 1 (out of 4) Safety-class 3 (out of 4) Your comment (can be edited when changing target decision) Target Rank? Ligandability-class 1 (out of 4) Safety-class 3 (out of 4) 7 Target Rank Your comment (can be edited when changing target decision) Safety-class 1 (out of 4) transient receptor potential cation channel subfamily V member 1 8 Ligandability-class 4 (out of 4) Safety-class 3 (out of 4) Tissue Expression-class 1 (out of 4) Tissue Expression-class 1 (out of 4) Tissue Expression-class 1 (out of 4) Target Rank? Tissue Expression-class 1 (out of 4) Therapeutic Evidence-class 1 (out of 3) Therapeutic Evidence-class 1 (out of 3) Therapeutic Evidence-class 1 (out of 3) Therapeutic Evidence-class 3 (out of 3) Benevolent 12#13DEMO Target Triage Overview Literature Biological Rationale ♡ Ligandability Safety Tissue Expression O Therapeutic Evidence Ⓒ Druggability Publication View paper September 2005 View paper December 2021 View paper January 2021 Rank 1 2 ✰ Programs ALS demo Oxidative stress in ALS ALS demo / prostaglandin-endoperoxide synthase 2 3 Back to the list. PTGS2 3 Match Absent on other lists i Overview Literature Biological Rationale Query 1 PTGS2 is a promising novel therapeutic target to decrease response to oxidative stress in amyotrophic lateral sclerosis. Top 100 sentences found in 70 unique publications. Top Enterprise score is 0.771 Enterprise score i ●0.771 0.726 Ⓒ 0.698 Where in publication text text Literature Enterprise Evidence Literature evidence relevant to the biological question according to the Enterprise model. Enterprise uses the name of the target and the components of the biological question to form a set of sentence-like queries. The model then finds and scores sentences from publications that are similar to each query, based on its understanding of the literature. text Query 1 PTGS2 is a promising novel therapeutic target to decrease response to oxidative stress in amyotrophic lateral sclerosis. Top 100 sentences found in 70 unique publications. Top Enterprise score is 0.771 Publication Rank Enterprise score Sentence from publication Where in nuhlication Sentence from publication Thus, COX-2 could play a partial role in neuronal damage, as suppression of its activity offers an incomplete neuroprotective effect in a mouse model of SOD1 related ALS. Was this helpful? 1 41 Therefore, the role of Cox-2, which is upregulated by SP1, in the oxidative stress state of neurons and glial cells. during the onset of ischemic stroke needs to be further explored. Was this helpful? 1 41 Neurotoxicity via elevating COX-2 expression was noted in neurodegenerative diseases, such as multiple sclerosis, amyotrophic lateral sclerosis, and Parkinson and Alzheimer diseases; meanwhile, the inhibition of COX 2 overossion promoted neuroprotective offorts according to coveral ovnorimonto 1.26 27 201 mplete 1641 glial cells 1641 tiple ion of 1641 eath in >>> 1 E Til#14TARGET VALIDATION Advanced in-house lab capabilities move programmes faster Cutting-edge technologies including invitro / in vico Biology, Chemistry, CMC, DMPK with in-house investment in CRISPR, RNA seq and human IPSC Work progresses rapidly from in-silico to in-vitro experimental test The more we do, the more we learn; experimental insights enrich our Knowledge Graph and enhance future target predictions Benevolent 14#15Proven to enhance drug discovery DISEASE-AGNOSTIC We can work on any therapeutic area due to the breadth and diversity of our data foundations. ACCELERATES DISCOVERY By combining our Al Platform, scientific expertise and wet lab facilities, we accelerate discovery and reduce discovery and development timelines. MODALITY-AGNOSTIC The Benevolent Platform™ can be applied to antibody and biologic targets, in addition to small molecule targets. IDENTIFIES NOVEL TARGETS Our predictive tools can surface targets that have never been considered for a disease before. BUILT FOR SCALE Our scalable and versatile Platform can support multiple in-house drug programmes and commercial collaborations. POTENTIAL TO INCREASE PROBABILITY OF SUCCESS By building higher confidence hypotheses in the earliest stages of drug discovery, we aim to reduce costly failures down the line. Benevolent 15#16Our prolific drug discovery engine drives higher productivity Number of new INDs filed by year by pharma and biotech companies. Median number of Phase I starts over five years (2015-2020)* Market cap¹ $211bn $288bn $281bn $263bn $122bn $140bn $108bn $0.5bn $18bn $74bn $79bn $29bn $1bn $5bn $0.5bn Companies with >20 commercialised products Companies with 3+ commercialised products Companies with <3 commercialised products AstraZeneca Pfizer Merck Roche sanofi AMGEN GILEAD Creating Possible Benevolent (Incyte) VERTEX REGENERON Alnylam sosel IONIS nektar Benevolent moderna DENALI Sangamo aclaris. EFFECTOR 1 2 2 2 N N 2 3 M 3 4 5 6 1-2 7 7 8 8 2-4 9 10 11 2027-31 AIM 2023-26 AIM 12 $0.5bn $69bn $4bn $1bn $1bn BenevolentAl potential productivity is in line with medium and large companies, but at a fraction of the total cost. BenevolentAl will aim to increase the number of INDS from its Platform with incremental cost largely from development through to the clinic only Note *IND filing rate is based on Phase I trial starts with the company as the lead sponsor. Average adjusted for companies which started clinical development during time period; ¹ Market cap as of 30/12/2022 (USD M) Source: clinicaltrials.gov; Company websites: L.E.K. research & analysis Benevolent 16#17Our flexible business model unlocks multiple routes to value creation Al-Discovery Tools Knowledge Graph Precision Medicine 000 B 000 Target Identification Molecular Design B C U GIND OWNED PIPELINE Platform-generated assets LICENSING Platform-generated assets PLATFORM COLLABORATIONS Economic Benefits NON-COMMERCIAL COLLABORATIONS ESG In-house development Out-licensed at IND, end Phase I or end II Platform Validation Platform Validation Data generated enriches the Benevolent Platform™ Data generated enriches the Benevolent Platform™ Benevolent 17#18Robust pipeline entirely generated by the Benevolent Platform™ BEN-2293 | Atopic Dermatitis BEN-8744 | Ulcerative Colitis BEN-28010 | Glioblastoma Multiforme BEN-9160 | Amyotrophic Lateral Sclerosis Inflammatory Bowel Disease Amyotrophic Lateral Sclerosis Antiviral Oncology Oncology Parkinson's Disease Nonalcoholic Steatohepatitis (NASH) Oncology Parkinson's Disease Fibrosis Inflammation Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Chronic Kidney Disease +10 Exploratory stage programmes Target ID Chemistry & Lead Opt AstraZeneca AstraZeneca Preclinical AstraZeneca 27.01.2021 15.12.2021 AstraZeneca 17.05.2022 06.10.2022 AstraZeneca 06.10.2022 Phase I Phase II Highlights • BEN-2293 - Phase Ib complete, Phase Ila ongoing • BEN-8744 - Novel target with zero prior linkage to UC. Delivered drug candidate within 2 years from programme initiation • All pipeline programmes generated using the Benevolent Platform™ Benevolent 18#19BEN-2293 Atopic Dermatitis (AD) ● Atopic dermatitis is the most common chronic inflammatory skin disease, characterized by intensely itchy, red, and swollen skin(¹) o Affects 10-20% of children and up to 3% of adults (2) o Approximately 60-70% of all cases present with mild-moderate disease severity(3) o Prevalence is rising (3), with market value in 7MM forecast to exceed $14 billion (2,4) • Skin inflammation and chronic pruritus associated with atopic dermatitis negatively impact quality of life and psychosocial well-being(¹) • Clear unmet need in mild to moderate patient segment for treatment addressing itch and inflammation, without side effects of steroids Topical best-in-class PanTrk inhibitor to relieve inflammation and rapidly resolve itch in patients with AD • BEN-2293 is a PanTrk inhibitor targeting TrkA,B and C receptors. The Trk receptors were identified as part of an effort to find mediators of both itch and inflammation in AD. Using our Molecular Design expertise we were able to design a Pan Trk inhibitor, equipotent against the 3 receptors BEN-2293 is expected to treat atopic dermatitis by: inhibiting itch signaling and blocking nerve sensitization (TrkA) in addition to inhibiting Thl and Th2-mediated dermal inflammation (TrkB, TrkC) • BEN-2293 will target Mild, Moderate and Severe Atopic Dermatitis patients, addressing unmet need in the treatment of mild to moderate Atopic Dermatitis as a steroid sparing alternative and in more severe patients undergoing treatment with systemics (e.g. dupilumab) that require add-on treatment Sources: (1) Weidinger et al. Nat Rev Dis Primers 2018; (2) GlobalData Report 2018: Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027; (3) GlobalData Report 2018: Atopic Dermatitis: Epidemiology Forecast to 2027; (4) Evaluate Pharma Benevolent 19#20BEN-2293 - indicative data from Phase Ib Caveats: • Phase lb was NOT powered to meaningfully assess efficacy - only 6 patients dosed with active per group • Maximum duration of dosing 14 days (EASI score changes typically measured at 28 days) Mean change from baseline Mean Change from Baseline %BSA affected in treated areas 14 day placebo treatment 1 0 -4 -5 -6 0 Cohort 3 Patients dosed 1% ointment, 30% BSA, once per day 1 2 3 Cohort 4 Patients dosed 1% ointment, 30% BSA, twice per day 4 EASI: Eczema Area and Severity Index 5 6 7 Day 8 9 10 11 12 13 14 15 0.25% QD 10%BSA 7d 1% QD 10%BSA 7d 1% QD 30%BSA 14d 1% BID 30%BSA 14d PBO 7d PBO 14 d Benevolent 20#21BEN-8744 Ulcerative Colitis (UC) Affects 0.4% US population), 1.7 million patients in 7MM), forecast $7.8bn market by 2026(2) • A chronic, lifelong disease that causes inflammation and ulceration of the inner lining of the colon and rectum • 64% of patients are mild-moderate, 31% of patients are moderate-severe and 5% of patients are severe-fulminant • Efficacy - 20-40% of Moderate-severe patients do not respond to anti-TNF (main treatment paradigm) (3) • Safety - Treatments have many side effects - from steroids to anti-TNF and JAK inhibitors (black box warnings) (4) • High unmet need for an alternative oral small molecule treatment option with improved safety profile and efficacy in treatment of refractory patients ● ● BEN-8744: Oral, peripherally-restricted, PDE10 inhibitor under development as a first-in-class treatment for refractory UC Phosphodiesterase 10 (PDE10) was identified by our TargetID platform as an entirely novel target for the treatment of UC/IBD Using our Molecular Design expertise we optimally designed a best in class peripherally restricted PDE10 inhibitor: BEN-8744 • BEN-8744 is expected to provide an efficacious disease modifying oral treatment for UC/IBD • BEN-8744 will target Moderate and Severe UC/IBD patients, meeting the unmet need left by existing therapies including: o Patients refractory to anti-TNFS or other biologics o Improved safety and tolerability profile compared to competitors o Aiming to use a Precision Medicine approach to target key responder patient cohorts and avoid the safety risks associated with ineffective therapies Sources: (1) GlobalData: Ulcerative Colitis, Global Drug Forecast and Market Analysis to 2026; (2) Evaluate Pharma: Gastro-intestinal, Inflammatory bowel disease (IBD), Ulcerative colitis, Worldwide Overview (report 17th Sep 2021); (3) Roda et al. Clin Transl Gastroenterol 2016; (4) Kobayashi et al Nat Rev Dis Primers 2020 and US FDA Drug Safety Communication 2021 Benevolent 21#22Target validation in colon tissue from ulcerative colitis patients Inflamed colonic mucosa biopsies from UC patients • Disease phenotype retained with high basal cytokine release • Readouts: IL6 and IL8 - key mediators of UC pathology Tissue samples treated with: • Target-selective tool compound (BEN-3218) • Positive controls - prednisolone and tofacitinib Selective target inhibition showed comparable reduction of IL-6 and IL-8 to the positive controls Validated as a target with a novel mechanism of action for ulcerative colitis (w/6d)9-11 20000 15000 10000 5000 0 Endoscopic Biopsy from UC patients IL-8(pg/ml) DMSO Prednisolone Tofacitinib BEN-3218 Inflammatory cytokine measurement 30000 20000 Colonic mucosa organ culture and compound treatment 10000 1 DMSO Prednisolone Tofacitinib BEN-3218 Benevolent 22#23BEN-8744 results and progress to date Target validation 2019 2020 2021 Novel, potent advanced lead molecule developed within 2 years TARGET IDENTIFICATION Novel target for UC Discovered using Benevolent TargetID tools PDE10 has zero linkage to UC in all available biomedical literature Experimentally validated in ex-vivo UC colon samples from patients refractory to SoC treatment Candidate nominated CHEMISTRY Rapid and efficient lead optimisation Preclinical development ✓ Molecular Design tools enabled rapid and efficient lead optimisation ✔ Candidate nominated in Sep '21 Novel, potent, selective, peripherally restricted PDE10. Inhibitor, with low dose prediction 2022 Delivered drug candidate within 2 years from programme initiation CTA Filed 2023 Phase I clinical study CLINICAL DEVELOPMENT Developing responder and progression endotypes We will develop responder and progression endotypes, adding molecular descriptors These will inform our trial design, patient selection and further target identification in UC Augmenting a further loop of iteration on an enriched graph Benevolent 23#24Robust pipeline entirely generated by the Benevolent Platform™ BEN-2293 | Atopic Dermatitis BEN-8744 | Ulcerative Colitis BEN-28010 | Glioblastoma Multiforme BEN-9160 | Amyotrophic Lateral Sclerosis Inflammatory Bowel Disease Amyotrophic Lateral Sclerosis Antiviral Oncology Oncology Parkinson's Disease Nonalcoholic Steatohepatitis (NASH) Oncology Parkinson's Disease Fibrosis Inflammation Chronic Kidney Disease Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Chronic Kidney Disease +10 Exploratory stage programmes Target ID Chemistry & Lead Opt AstraZeneca AstraZeneca Preclinical AstraZeneca 27.01.2021 15.12.2021 AstraZeneca 17.05.2022 06.10.2022 AstraZeneca 06.10.2022 Phase I Phase II Highlights Focus on complex multifactorial diseases • Broad therapy area coverage enabled by disease-agnostic Platform, with future investment to focus on three therapeutic indications • Balance of risk between "best in class" and "first in class" drug candidates • Potential for rapid scaling and expansion into new modalities Benevolent 24#25Strategic validation: successful collaboration with AstraZeneca Multi-year Target-ID collaboration is delivering multiple, novel targets for complex diseases with high unmet need Separate data environment established to integrate AstraZeneca's data into a bespoke Knowledge Graph BenevolentAl and AstraZeneca teams working in close collaboration to explore, identify and validate targets Deal structure of upfront license fee, milestone payments and downstream royalties Data generated via the collaboration enriches the Benevolent Platform™ AstraZeneca Five novel targets selected for AstraZeneca's portfolio to date 2019 Initial deal focussed on Chronic Kidney Disease & Idiopathic Pulmonary Fibrosis 2022 3-year collaboration expansion to include Heart Failure & Systemic lupus erythematosus#26Using our platform for wider societal benefit Identified a COVID-19 treatment now approved for use by the FDA RAPID Identified baricitinib as a treatment in just 48 hours, published research in The Lancet in Feb 2020 NOVEL Our technology and Al workflows identified a previously unknown antiviral mechanism (¹) EFFECTIVE COV-BARRIER trial showed baricitinib reduces mortality by 38% in hospitalised patients(2), and by 46% in ventilated or ECMO patients (3) FDA FDA approved the baricitinib to treat COVID-19 in May 2022(4) after first granting EUA in Nov 2020 (5) Lilly Led to equity investment from Eli Lilly DNDi Drugs for Neglected Diseases initiative Non-commercial collaboration → Focused on Dengue fever - a major healthcare burden → Aims to deliver biological targets and drug repurposing candidates → Experimental validation in progress - 6 assays#27World-class team We "build tech in the service of science" 48% Drug Discovery Bus Ops As of December 2022 15% 350+ World Class Scientists & Technologists 37% Tech Board of Industry Luminaries Combines deep expertise across Al, pharma, & drug discovery & development Baroness Joanna Shields CEO & Executive Director Jean Raby Non-Executive Director François Nader Chairman Jackie Hunter Non-Executive Director Susan Liautaud Non-Executive Director Nigel Shadbolt Non-Executive Director Olivier Brandicourt Non-Executive Director John Orloff Non-Executive Director Benevolent 27#28Poised for growth: multiple value inflection points Internal pipeline depth and progression AZ Collaboration Other Platform Collaborations H1 2023 BEN-2293: AD Data expected Q1 2023 BEN-8744: UC Begin Phase I study H1 2023 H2 2023 BEN-2293: AD Out-licensing BEN-28010: GBM Submit Clinical Trial Application (CTA) Expect to add 4-6 names drug programmes to portfolio 2024 BEN-8744: UC Phase I data package 2024, with Phase II to follow shortly after BEN-28010: GBM Initiate Phase I study Aim to progress 1-2 CTA/IND stage drug candidates every year Discussions with a number of parties ongoing Potential new targets added for SLE and Heart Failure - prior targets (3 for IPF and 2 for CKD) advancing Benevolent 28#29Ⓡ Because benevolent.com @benevolent_ai A matters in benevolentai [email protected]